Amin Zulkifli, Rahmawati Fitriana N
Internal Medicine Department, Faculty of Medicine, University of Indonesia, Cipto Mangunkusumo Hospital, Jakarta, Indonesia. E-mail.
Saudi Med J. 2017 Apr;38(4):344-349. doi: 10.15537/smj.2017.4.15843.
Acute respiratory distress syndrome (ARDS) is an acute inflammatory lung injury, characterized by increased pulmonary capillary endothelial cells and alveolar epithelial cells permeability leading to respiratory failure in the absence of cardiac failure. Despite recent advances in treatments, the overall mortality because of ARDS remains high. Biomarkers may help to diagnose, predict the severity, development, and outcome of ARDS in order to improve patient care and decrease morbidity and mortality. This review will focus on soluble receptor for advanced glycation end-products, soluble tumor necrosis factor-receptor 1, Interluken-6 (IL-6), IL-8, and plasminogen activator inhibitor-1, which have a greater potential based on recent studies.
急性呼吸窘迫综合征(ARDS)是一种急性炎症性肺损伤,其特征是肺毛细血管内皮细胞和肺泡上皮细胞通透性增加,在无心力衰竭的情况下导致呼吸衰竭。尽管近年来治疗取得了进展,但ARDS导致的总体死亡率仍然很高。生物标志物可能有助于诊断、预测ARDS的严重程度、发展及预后,以改善患者护理并降低发病率和死亡率。本综述将聚焦于晚期糖基化终产物可溶性受体、可溶性肿瘤坏死因子受体1、白细胞介素-6(IL-6)、IL-8和纤溶酶原激活物抑制剂-1,基于近期研究,它们具有更大的潜力。